Arysta Lifescience India Profile
Key Indicators
- Authorised Capital ₹ 105.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 4.98 Cr
as on 24-10-2024
- Company Age 75 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 38.45%
(FY 2023)
- Profit 152.61%
(FY 2023)
- Ebitda 138.26%
(FY 2023)
- Net Worth 66.22%
(FY 2023)
- Total Assets 192.61%
(FY 2023)
About Arysta Lifescience India
The Corporate was formerly known as Devidayal (Sales) Limited. The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 105.00 Cr and a paid-up capital of Rs 4.98 Cr, as per Ministry of Corporate Affairs (MCA) records.
Arun Ashar, Swati Mayekar, Sameer Tandon, and Two other members serve as directors at the Company.
- CIN/LLPIN
U51420MH1949PLC007856
- Company No.
007856
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
07 Nov 1949
- Date of AGM
15 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Arysta Lifescience India Limited offer?
Arysta Lifescience India Limited offers a wide range of products and services, including Essential & Aromatic Oils, Menthol, Insecticides and Pesticides, Fungicides.
Who are the key members and board of directors at Arysta Lifescience India?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arun Ashar  | Director | 31-May-2019 | Current |
| Swati Mayekar | Director | 18-May-2020 | Current |
| Sameer Tandon | Director | 13-Jan-2020 | Current |
| Meena Ved | Director | 18-May-2020 | Current |
| Ashish Dobhal | Director | 07-Jul-2019 | Current |
Financial Performance of Arysta Lifescience India.
Arysta Lifescience India Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 38.45% increase. The company also saw a substantial improvement in profitability, with a 152.61% increase in profit. The company's net worth Soared by an impressive increase of 66.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Arysta Lifescience India?
In 2023, Arysta Lifescience India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Arysta Lifescience India?
Arysta Lifescience India has a workforce of 254 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Arysta Lifescience India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Arysta Lifescience India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
